These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 36044733)
1. Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors. Asadi M; Xie WJ; Warshel A J Am Chem Soc; 2022 Sep; 144(36):16638-16646. PubMed ID: 36044733 [TBL] [Abstract][Full Text] [Related]
2. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879 [TBL] [Abstract][Full Text] [Related]
3. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305 [TBL] [Abstract][Full Text] [Related]
4. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor. Kriegsmann K; Kriegsmann M; Witzens-Harig M Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636 [TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125 [TBL] [Abstract][Full Text] [Related]
6. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C Front Immunol; 2019; 10():2129. PubMed ID: 31552054 [TBL] [Abstract][Full Text] [Related]
7. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545 [TBL] [Abstract][Full Text] [Related]
8. Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. Podoll T; Pearson PG; Evarts J; Ingallinera T; Bibikova E; Sun H; Gohdes M; Cardinal K; Sanghvi M; Slatter JG Drug Metab Dispos; 2019 Feb; 47(2):145-154. PubMed ID: 30442651 [TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors. Sharma A; Thelma BK J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362 [TBL] [Abstract][Full Text] [Related]
10. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794 [TBL] [Abstract][Full Text] [Related]
11. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871 [TBL] [Abstract][Full Text] [Related]
12. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. da Cunha-Bang C; Niemann CU Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220 [TBL] [Abstract][Full Text] [Related]
14. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure. O'Riordan CE; Purvis GSD; Collotta D; Krieg N; Wissuwa B; Sheikh MH; Ferreira Alves G; Mohammad S; Callender LA; Coldewey SM; Collino M; Greaves DR; Thiemermann C Front Immunol; 2020; 11():581758. PubMed ID: 33162995 [TBL] [Abstract][Full Text] [Related]
15. Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib. Barragan AM; Ghaby K; Pond MP; Roux B J Chem Inf Model; 2024 Apr; 64(8):3488-3502. PubMed ID: 38546820 [TBL] [Abstract][Full Text] [Related]
16. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. Miao Y; Xu W; Li J Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396 [TBL] [Abstract][Full Text] [Related]
17. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Qiu H; Ali Z; Bender A; Caldwell R; Chen YY; Fang Z; Gardberg A; Glaser N; Goettsche A; Goutopoulos A; Grenningloh R; Hanschke B; Head J; Johnson T; Jones C; Jones R; Kulkarni S; Maurer C; Morandi F; Neagu C; Poetzsch S; Potnick J; Schmidt R; Roe K; Viacava Follis A; Wing C; Zhu X; Sherer B Bioorg Med Chem; 2021 Jun; 40():116163. PubMed ID: 33932711 [TBL] [Abstract][Full Text] [Related]
18. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer. Benner B; Carson WE J Hematol Oncol; 2021 Jan; 14(1):15. PubMed ID: 33441177 [TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M Front Immunol; 2021; 12():766272. PubMed ID: 34912339 [TBL] [Abstract][Full Text] [Related]
20. Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors. Su R; Diao Y; Sha W; Dou D; Yu Z; Leng L; Zhao Z; Chen Z; Li H; Xu Y Bioorg Chem; 2022 Sep; 126():105860. PubMed ID: 35661525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]